An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- Report: Speed up drug development with artificial intelligenceon January 22, 2020 at 2:04 pm
“Machine learning holds tremendous potential in drug development,” according to the two-part report released Tuesday, which said such technologies could cut down the current time of about 10 to 15 ...
- Sanofi CEO Paul Hudson on the coronavirus, the FDA, drug development and moreon January 22, 2020 at 8:18 am
Paul Hudson, CEO of Sanofi, joins "Squawk Box" at the World Economic Forum in Davos to discuss the first U.S. case of the coronavirus that originated in China, new drug development and more.
- Machine Learning in Drug Development Requires Data Access, Standardson January 22, 2020 at 8:15 am
January 22, 2020 - Machine learning algorithms have the potential to accelerate and refine the drug development process, but the industry should expand data access and create consistent data standards ...
- Data challenges hinder machine learning in drug developmenton January 21, 2020 at 9:25 pm
While machine learning has the potential to identify new treatments, reduce failure rates in clinical trials and improve drug development, a lack of high-quality data is hindering the use of the ...
- New opportunity for cancer drug developmenton January 21, 2020 at 11:16 am
"This is a breakthrough laying the basis for development of novel and improved compounds that target FZDs for the treatment of different types of cancer." Key to the discovery was on the one hand a ...
- Machine Learning Could Speed Drug Development, GAO Sayson January 21, 2020 at 11:05 am
GAO offered that ML could accelerate drug development by screening chemical compounds, and “zero in on promising drug candidates in less time” than it currently takes to do so. “Machine learning is ...
- Nina Nguyen - Private sector investment fuels drug developmenton January 21, 2020 at 5:05 am
Some members of Congress underestimate how crucial private sector investment is to drug development. They believe that scientists at the National Institutes of Health develop the majority of new drugs ...
- University of Michigan partnership with pharmaceutical company promotes drug developmenton January 18, 2020 at 9:57 am
ANN ARBOR, Mich. – A new partnership between the University of Michigan and Sun Pharma Advanced Research Company, an international biopharmaceutical company, will springboard the development of new ...
- Finding has major ramifications for ongoing drug development against MLL-rearranged leukemiaon January 17, 2020 at 5:36 am
Second, the finding has important ramifications for ongoing drug development against MLL-rearranged childhood leukemia, namely that drugs affecting the healthy MLL gene along with the rearranged form ...
- Organs-on-Chips Centre opens in UK for advancements in medical research and drug developmenton January 16, 2020 at 7:47 am
A new research centre which aims to revolutionise medical research and drug development using microengineered Organs-on-Chips has opened at Queen Mary University of London. Organs-on-Chips contain ...
via Bing News